NCT06095362View on ClinicalTrials.gov

Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 29, 2021

Primary Completion Date

October 12, 2023

Study Completion Date

October 12, 2023

Conditions
Thyroid CarcinomaSurgery
Interventions
DRUG

Bevacizumab-IRDye800CW

All patients will receive a dose of Bevacizumab-IRDye800CW, in a dose of 4.5, 10, or 25mg

Trial Locations (1)

9713 GZ

University Medical Center Groningen, Groningen

All Listed Sponsors
collaborator

Dutch Cancer Society

OTHER

lead

University Medical Center Groningen

OTHER

NCT06095362 - Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW | Biotech Hunter | Biotech Hunter